Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Drug discovery and development

Database of anti-ageing compounds launched

A database of anti-ageing compounds has been created by scientists at the University of Liverpool and the Biogerontology Research Foundation, a UK charity devoted to finding treatments for the diseases of ageing.

DrugAge includes data on 418 different drugs and compounds that have been found to extend healthy life.

The publicly accessible database has been compiled following scrutiny of published data from experiments involving 27 model organisms, including yeast, worms, flies and mice.

When the researchers analysed these data, they discovered that most age-related pathways have not been explored pharmacologically, which “suggests that there is still plenty of scope for the discovery of new lifespan-extending and healthspan-extending compounds”, they say.

The new database — which includes a profile of each compound including data on its biochemistry and bioactivity, its life-extending effects and current drug status — has been launched, 18 months after the academics highlighted the initiative in the journal Aging[1].

They said in September 2015 that they wanted to provide a “one-stop resource for researchers interested in anti-aging compounds, saving countless hours of data mining, literature review, and expert analysis”.

Launching the database on 14 March 2017, Franco Cortese, deputy director and trustee of the Biogerontology Research Foundation, described it is a “landmark resource”.

He said: “Analysis performed using the database has already revealed interesting trends, including a modest but statistically significant overlap between lifespan-extending drugs and known age-related genes, a strong correlation between average/median lifespan changes and maximum lifespan changes, a strong correlation between the lifespan-extending effects of compounds between males and females, and, perhaps most significantly, that most known age-related pathways have yet to be targeted pharmacologically.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202455

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • DrugAge website screenshot

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.